
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 14, 2020**

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36306
(Commission File Number)

20-8179278
(IRS Employer Identification No.)

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ
(Address of principal executive offices)

07677
(Zip Code)

Registrant's telephone number, including area code: **(201) 326-5300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock (par value \$0.001 per share)	EGRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On September 14, 2020, Eagle Pharmaceuticals, Inc., or the Company, released an updated investor presentation of the Company's business model, products, and product candidates. The investor presentation will be used from time to time in meetings with investors.

A copy of the above-referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation of the Company dated September 2020
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 14, 2020

EAGLE PHARMACEUTICALS, INC.

By: /s/ Scott Tarriff

Scott Tarriff

Chief Executive Officer

Eagle Pharmaceuticals

NASDAQ: EGRX
September 2020



CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved.

Forward Looking Statements

This presentation contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as "anticipated," "forward," "will," "would," "may," "remain," "potential," "prepare," "expected," "believe," "plan," "near future," "belief," "guidance," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events such as: the number and timing of potential product launches, development initiatives and new indications for RYANODEX; the timing of potential product launches for Vasopressin; the Company's clinical development plan for its fulvestrant product candidate, EA-114, as well as the development efforts for the other product candidates in its portfolio; the potential benefits and efficacy of RYANODEX, including the potential for RYANODEX as a treatment for nerve agent exposure, acute radiation syndrome, traumatic brain injury, Alzheimer's disease (EA-112) and additional indications; the timing, scope or likelihood of regulatory filings and approvals from the FDA for the Company's product candidates, including the Company's ability to work with the FDA to finalize the Special Protocol Assessment and advance the development of RYANODEX for brain damage secondary to nerve agent exposure; the potential for other products treating the same indication as BENDEKA entering the market before 2022; the timing of the Company's PEMFEXY launch, if ever; the success of the Company's collaborations with its strategic partners and the timing and results of these partners' preclinical studies and clinical trials; the ability of the Company's fulvestrant product candidate, EA-114, to improve clinical outcomes for post-menopausal metastatic breast cancer patients; the Company's timing and ability to enroll patients in ongoing and upcoming clinical trials; the ability of the Company to obtain and maintain coverage and adequate reimbursement for its products; the implementation of certain healthcare reform measures; the Company's timing and ability to repurchase additional shares of the Company's common stock, if any, under its share repurchase program; the Company's ability to deliver value in 2020 and over the long term; and the Company's plans and ability to advance the products in its pipeline. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the COVID-19 pandemic, including disruption or impact in the sales of the Company's marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company's third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic on the Company's business, financial condition and results of operations; risks that the Company's business, financial condition and results of operations will be impacted by the spread of COVID-19 in the geographies where the Company's third-party partners operate; whether the Company will incur unforeseen expenses or liabilities or other market factors; risks that results from in vitro laboratory tests of RYANODEX are not necessarily predictive of future clinical trial and in vivo results; whether the Company will successfully implement its development plan for its fulvestrant product candidate, EA-114, or other product candidates; delay in or failure to obtain regulatory approval of the Company's product candidates; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners, including the University of Pennsylvania, Teva, Tyme and NorthShore University HealthSystem and the parties' ability to work effectively together; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of our products or that may have an impact on any of our products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; and those risks and uncertainties identified in the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2019 as updated by the company's subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Non-GAAP Financial Performance Measures


In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted non-GAAP net income and adjusted non-GAAP earnings per share attributable to Eagle. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information.

Adjusted non-GAAP net income excludes stock-based compensation expense, depreciation expense, amortization expense, expense of acquired in-process research and development, severance, non-cash interest expense, debt issuance costs, gain on sale of assets, changes in fair value of contingent consideration, asset impairment charge, restructuring charge, legal settlement expense related to collaboration with Tyme, fair value adjustments on equity investment, and the tax effect of these adjustments. The Company believes these non-GAAP financial measures help indicate underlying trends in the Company's business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company's baseline performance before items that are considered by the Company not to be reflective of the Company's ongoing results. See the annexed Reconciliation of GAAP to Adjusted Non-GAAP Net Income and Adjusted Non-GAAP Earnings per Share and Reconciliation of GAAP to Adjusted Non-GAAP EBITDA for details of the amounts excluded and included to arrive at adjusted non-GAAP net income, adjusted non-GAAP earnings per share amounts, and adjusted non-GAAP EBITDA amounts, respectively.

These adjusted measures are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. The Company strongly encourages investors to review its consolidated financial statements and publicly-filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Eagle Pharmaceuticals Snapshot

Committed to developing innovative medicines that result in meaningful improvements in patients' lives with a focus on underserved therapeutic areas



Fully integrated R&D, clinical, manufacturing, quality, and commercial



Profitable with foundation for continued long-term growth



CNS/metabolic critical care and oncology focus



Pipeline at near-term inflection point

Strong Foundation for Potential Long-Term Growth

Highly efficient business model:

Invested \$217mm (21%+ of revenue) in R&D since 2013

Sustainable profitability:

\$271mm* in cash flow from operations (2015 – 2Q 2020)

* excluding receivables build


Successful capital reinvestment:

\$180mm repurchased since August 2016; only 13.6mm basic shares outstanding

Robust balance sheet:

No net debt and flexibility to actively deploy capital for opportunities

Recent Developments



10 Programs - Potential for 5 Launches in the Next 3 Years

CNS/METABOLIC CRITICAL CARE


Product	Indication	Potential Market Advantage	Development Stage	In-House/Partnership
RYANODEX*	1. Nerve Agent (NA) Exposure	First in class	Submitted SPA on 8/28 to FDA; plan to start second animal species study and file NDA in 1H 2021	 United States Army Medical Research Institute of Chemical Defense
	2. Acute Radiation Syndrome (ARS)	First in class	Completed POC study; entering first of two registration animal studies under FDA Animal Rule; next, Eagle will conduct a GLP study in a validated animal model	 (in-house)
	3. Traumatic Brain Injury (TBI)/ Concussion	First in class	Preclinical animal study in progress; expect study results with NorthShore University HealthSystem before year-end	NorthShore University HealthSystem Dr. Julian Bailes
	4. Alzheimer's Disease (AD)	First in class	Completed preclinical animal study	 University of Pennsylvania
	5. Anti-viral	First in class	Preclinical	 (in-house)
EA-111	6. NCE related to dantrolene	First in class	Preclinical and toxicology studies in progress	 (in-house)
VASOPRESSIN*	7. Increase blood pressure during vasodilatory shock	First to file*	Anticipate vasopressin launch with 180-day market exclusivity; patent trial delayed due to COVID-19 – no date set yet	 (in-house)

CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved.

* Royalty obligation
† First to file ANDA referencing VASOSTRICT; submission accepted for filing by FDA March 2018

10 Programs - Potential for 5 Launches in the Next 3 Years

ONCOLOGY

Product	Indication	Potential Market Advantage	Development Stage	In-House/Partnership
SM-88	8. Pancreatic Cancer (multiple indications)	First in class	Pivotal studies underway 	 Tyme Technologies
EA -114 (fulvestrant)	9. HR+ Advanced Breast Cancer (BC)	Best in class	Received additional positive data from pilot study; will meet with FDA in late October 	 (in-house)
PEMFEXY* (liquid injection)	10. Nonsquamous Non-Small Cell Lung Cancer (NSCLC) – malignant pleural mesothelioma	First to market	Approval granted on February 10, 2020; Q1 2022 launch; unique J-code established by CMS; granted supplement approval for 500mg multiple-dose vial 	 (in-house)

* Royalty obligation

CNS/Metabolic Critical Care Pipeline Opportunities

CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved.

9


EAGLE
PHARMACEUTICALS

RYANODEX[®] (dantrolene sodium) injectable suspension

Breakthrough formulation


- Approved July 2014
- Launched August 2014

Currently indicated for the treatment of malignant hyperthermia (MH) in conjunction with appropriate supportive measures, and for the prevention of MH in patients at high risk




RYANODEX: Building a Successful Franchise

New indications under development*



Nine U.S. patents issued to date, expiring between 2022 and 2025

CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved. *Potential indications under development



RYANODEX[®]
(dantrolene sodium)

◀ Mechanism of action

RYANODEX Potential in Traumatic Brain Injury (TBI)/Concussion



1. Dewan, MC, et al. Estimating the global incidence of traumatic brain injury. *J. Neurosurg.* 2018;(130):1-18. doi: 10.3171/2017.10.
2. Centers for Disease Control and Prevention (CDC). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths—United States, 2014. CDC, U.S. Department of Health and Human Services. 2019. Accessed at https://www.cdc.gov/traumaticbraininjury/pdf/TBI-Surveillance-Report-FINAL_508.pdf.

- **Currently there is no FDA-approved drug to treat TBI/concussion, which is estimated to affect 69 million people worldwide¹**
 - The CDC estimates that in 2014, there were nearly 2.8 million TBI-related emergency department visits in the U.S, some of which resulted in long-term harm or death. Up to 1/3 of cases occurred in children²
- **Eagle announced a research partnership with NorthShore University HealthSystem in January 2020**
 - Studying dantrolene sodium for TBI/concussion in animal models to determine if it can help halt or repair the harm caused by these traumas
- **Expect study results with NorthShore University HealthSystem before year-end**

CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved.

RYANODEX (EA-112) Potential in Alzheimer's Disease

A completely novel approach to the disease



- **Alzheimer's disease is one of the greatest medical challenges of our time**, with limited treatment options. It is the most common form of dementia and fifth-leading cause of death¹ affecting more than 30 million people worldwide²
- **Eagle and UPenn concluded that calcium dysregulation may play a unique role in Alzheimer's disease**
 - Results from a proof-of-concept preclinical study presented at the July 2019 Alzheimer's Association International Conference showed that intranasal administration of dantrolene sodium provided therapeutic effects on memory and cognition in a mouse model of Alzheimer's

Promising Progress in Research on Dantrolene for Alzheimer's Disease (AD)

- Our partner UPenn conducted a recent animal study demonstrating:
 - A novel route of administration:
 - Greater passage of dantrolene across the blood brain barrier
 - Higher brain concentrations of dantrolene
 - A disease modifying effect:
 - Significantly improved memory
 - Significantly improved cognition
 - No significant side effects were detected in mortality, olfaction, motor or liver functions
 - Results were pronounced, especially after the start of amyloid accumulation and cognitive dysfunction
- Publication of Preclinical Study of Intranasal Dantrolene in August 18, 2020 *Journal of Alzheimer's Disease*



RYANODEX Potential for Nerve Agent (NA) Exposure

First-of-its kind neuroprotective treatment for the amelioration of brain damage due to nerve agent exposure and, if approved, may receive orphan drug exclusivity (ODE) for organophosphate exposure



Nerve agents are the most toxic of the known chemical warfare agents

- Rapid treatment with available agents decreases risk of mortality but does not ameliorate risk of brain damage. NA survivors may experience permanent neurologic damage and death
- Agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to evaluate the neuroprotective effects of RYANODEX in an accepted NA model
- Results of study conducted with USAMRICD demonstrated a statistically significant reduction in brain damage secondary to NA exposure in RYANODEX-treated animals, compared with controls (p value ≤ 0.04)
- Submitted a Special Protocol Assessment to FDA on August 28th; 45-day review period. If mutual agreement on protocol with FDA, plan to start study and file NDA in 1H 2021



RYANODEX Potential in Acute Radiation Syndrome

Acute radiation syndrome (ARS), or radiation sickness, is a serious illness that can happen when a person is exposed to very high levels of radiation, usually over a short period of time



- Exploring investigational indication for RYANODEX for treatment of hematopoietic syndrome in individuals exposed to high doses of radiation, such as nuclear power plant leakage or nuclear weapons. Potential to apply to certain cancer patients undergoing radiation therapy; additional research opportunity.
- In a proof-of-concept study in a Total-Body Irradiation Animal Model, the RYANODEX treatment group had overall less mortality post-treatment than nontreated animals
- Next, Eagle will conduct a GLP study in a validated animal model

EA-111 (New Chemical Entity)

Developing the next generation of ryanodine receptor antagonists



- **Significant benefits of an intramuscular (IM) formulation**
 - EA-111 would allow for easier and more rapid administration in emergency situations (military and civilian)
 - Enables point-of-care administration to patients in need
 - Eliminates IV-infusion

Vasopressin



- Indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
- Generic version of Par Sterile Products, LLC (an Endo International plc company) original VASOSTRICT®
- \$694 million in brand sales LTM¹
- Eagle is first-to-file an ANDA referencing VASOSTRICT for the 20 units per ml presentation, which ANDA was submitted in March 2018
- Patent trial with the Par entities delayed due to COVID-19 – no date set yet; FDA’s 30 month stay from approving VASOSTRICT ANDA ends in October 2020
- Anticipate vasopressin launch with 180-day market exclusivity

Oncology Pipeline Opportunities

CONFIDENTIAL
© 2020 Eagle Pharmaceuticals, Inc. All rights reserved.

20

EAGLE
PHARMACEUTICALS

EA-114: Our Fulvestrant Product Candidate for HR+ Advanced Breast Cancer

Impact of Advanced Breast Cancer

- ~75% of breast cancers are HR+¹
- ~30% of patients first diagnosed with early-stage disease eventually develop metastatic disease²
- 27% five-year survival for patients in U.S. with metastatic breast cancer³

An Unmet Need


- Eagle's 600-subject PK trial yielded ~18,000 data points, which we mined for insights
- For fulvestrant to work, it needs to bind to and block the estrogen receptor (ER)
- Not everyone treated with fulvestrant achieves the desired result – a substantial number of women with advanced HR+ breast cancer receiving standard treatment experience early disease progression
- Currently, low ER inhibition is an important factor resulting in suboptimal treatment, which may lead to faster progression of the disease
- Our research suggests Eagle's product could substantially improve the clinical outcomes for these post-menopausal metastatic breast cancer patients




1. Keen JC, Davidson NE. The biology of breast carcinoma. *Cancer* 2003;97:825–33. DOI: 10.1002/cncr.11126 2. Zhao H, et al. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. *Dove Press*. 27 September 2018. DOI <https://doi.org/10.2147/CMAR.S178395>. 3. Howlader N, et al (eds). *SEER Cancer Statistics Review, 1975-2016*, National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER website, April 2019.

Fulvestrant

competitively inhibits estrogen-stimulated cell division by binding to the estrogen receptor



EA-114 (Fulvestrant) Research Progress¹



Collaboration with Tyme Technologies for Cancer Metabolism-Based Compound for Pancreatic Cancer, Currently in Late-Stage Trials




- Tyme is a biotechnology company focused on exploring novel therapeutic approaches designed to target cancer's unique metabolism
- Tyme is advancing proprietary Cancer Metabolism-Based Therapies (CMBTs™) for difficult-to-treat cancers

SM-88

- SM-88 is a novel investigational agent in two Phase II/III studies for pancreatic cancer, one phase II trial in sarcoma and recently completed a Phase II study for prostate cancer
- SM-88 has demonstrated encouraging tumor responses in 15 different cancer types

Oral SM-88 Represents Novel Therapeutic Approach

- Designed to selectively disrupt protein synthesis in cancer cells with demonstrated tumor responses in 15 cancer types across multiple studies
- Tyme-88-PANC pivotal trial launched in January 2020 to evaluate oral SM-88 for third-line treatment of patients with metastatic pancreatic cancer
- In a Phase II study of patients with actively progressing metastatic pancreatic cancer who had failed previous therapy, evaluable patients on SM-88 demonstrated median overall survival of 6.4 months as of April 25, 2019
- SM-88 was well tolerated with 2% of patients reporting a grade 3/4 serious adverse event across trials
- Patients who achieved stable disease or better demonstrated a statistically significant (p value =0.02) improvement in survival with a 92% reduction in risk of death



SM-88 Data from Pivotal Trial Expected in 2021



- Eagle and Tyme have entered into a share purchase agreement (SPA) and a co-promotion agreement for SM-88 in the U.S. Eagle paid an initial \$20 million up front
- In addition, Eagle may invest an additional \$20 million in Tyme upon achievement of certain milestones, \$10 million of which would be an additional purchase of equity in Tyme. Eagle has certain promotion rights to all indications for SM-88 in the U.S. Tyme retains all commercial rights to SM-88 outside the U.S. and may buy out Eagle's U.S. rights under the co-promotion agreement at any time for \$200 million
- Under the co-promotion agreement, Tyme will be responsible for all development, regulatory, manufacturing and marketing costs associated with SM-88, as well as 75% of the promotional effort. Eagle will be responsible for 25% of the promotional effort and shall receive 15% of all net sales in the U.S.

Oncology Assets: Building From Our Successes



Highly successful franchise

BENDEKA royalty increase: from 25% to 30% on 10/1/19 and then increases by 1 percentage point on each anniversary thereafter until it reaches 32%

Courts upheld patent infringement claims as valid; defendants enjoined from launching ANDA products before 2031

Appellate Court confirmed ODE for BENDEKA through 12/7/2022

Established royalty revenue beyond 2025

Long-term cash flow stream

15 Orange Book listed patents through 2031 and unique J-code

FDA's petition for re-hearing *en banc* of Appellate ODE decision denied, confirming bendamustine franchise exclusivity through December 2022

Reached settlement agreement with Lilly on 12/13/2019

Approval granted on February 10, 2020; allows for initial entry of PEMFEXY – a liquid formulation – of approximately three-week supply of current ALIMTA® utilization on Feb. 1, 2022, and a subsequent uncapped entry on April 1, 2022

ALIMTA® U.S. LTM sales as of June 30, 2020 were \$1.2 billion¹

Generic entrants blocked until 05/24/22

CMS established unique J-Code; FDA granted supplement approval for 500mg multiple-dose vial

Symbio TREAKISYM, Japanese licensing partner

\$5 million milestone payment upon approval of either TREAKISYM Ready-to-Dilute (RTD), or Rapid Infusion (RI) product

Royalties and milestones of \$10 to \$25 million per year if Symbio first launches TREAKISYM RTD and then its RI product

Anticipating three new product launches in 2022 (PEMFEXY, EA-114, & SM-88)

Multiple Near-Term Value Inflection Points

Profitable with a robust balance sheet, no net debt, and ample capital for strategic transactions

- 10 key initiatives underway with the potential for 5 product launches over the next 3 years
 - Each has the potential to be either first-in-class, first-to-market, or best-in-class
 - Seven CNS/metabolic critical care products (TBI/concussion, ARS, NA, Alzheimer's, anti-viral, EA-111, vasopressin)
 - Three oncology products (pancreatic cancer, advanced breast cancer, and lung cancer)
 - BENDEKA: ODE affirmed/*en banc* denied; patent infringement claims upheld against ANDA holders
 - All focus on underserved therapeutic areas
- Complementary scientific and research partnerships/collaborations
 - U.S. Military (nerve agent exposure)
 - NorthShore University HealthSystem (TBI/concussion)
 - University of Pennsylvania (Alzheimer's disease)
- Comprehensive IP portfolio to ensure future growth
- Robust growth plan includes organic development and strategic transactions

Appendix

Reconciliation of GAAP to Adjusted Non-GAAP Net Income and Adjusted Non-GAAP EPS (unaudited)

(in thousands, except share and per share amounts)	Twelve Months Ended December 31,				
	2019	2018	2017	2016	2015
Net income - GAAP	\$ 14,313	\$ 31,903	\$ 51,943	\$ 81,453	\$ 2,571
Adjustments:					
Cost of product revenues:					
Amortization of acquired intangible assets (1)	900	895	1,194	746	-
Research and development:					
Share-based compensation expense	4,442	4,014	3,942	2,914	1,271
Depreciation	286	470	74	-	-
Expense of acquired in-process research & development	500	1,700	1,000	-	-
Severance	455	466	-	-	-
Selling, general and administrative:					
Share-based compensation expense	17,556	15,068	11,487	6,853	2,780
Amortization of acquired intangible assets (2)	1,620	1,620	1,620	203	-
Depreciation	686	685	858	640	112
Debt issuance costs	88	-	286	-	-
Severance	-	-	268	-	-
Other:					
Gain on sale of asset (3)	-	-	-	(1,750)	-
Non-cash interest expense	480	376	238	8	-
Change in fair value of contingent consideration (4)	-	(763)	(7,378)	957	-
Asset impairment charge	-	2,704	7,235	-	-
Restructuring charge	-	7,911	-	-	-
Legal settlement	-	-	1,650	-	-
Tax effect of the Non-GAAP adjustments (5)	(4,433)	(7,894)	(5,368)	(45,103)	-
Adjusted Non-GAAP Net income	\$ 36,893	\$ 59,155	\$ 69,049	\$ 45,921	\$ 6,734
Adjusted Non-GAAP earnings per share					
Basic	\$ 2.68	\$ 4.01	\$ 4.57	\$ 2.96	\$ 0.44
Diluted	\$ 2.61	\$ 3.87	\$ 4.34	\$ 2.79	\$ 0.41
Weighted number of common shares outstanding:					
Basic	13,754,516	14,768,625	15,102,890	15,533,681	15,250,154
Diluted	14,138,733	15,278,651	15,908,211	16,434,104	16,253,781

EXPLANATION OF ADJUSTMENTS:

- 1) Amortization of intangible assets for RYANODEX and Docetaxel
- 2) Amortization of intangible assets for Eagle Biologics
- 3) Gain on divestiture of diclofenac-misoprostol
- 4) Changes in the fair value of contingent consideration (Docetaxel and Eagle Biologics)
- 5) Reflects the estimated tax effect of the pretax adjustments, \$3.4 million of tax expense from U.S. tax reform, which is reflected in 2017 and the reversal of a tax valuation allowance in 2016

Reconciliation of GAAP to Adjusted Non-GAAP EBITDA (unaudited)

(in thousands)	Twelve Months Ended June 30,	Twelve Months Ended December 31,				
	2020	2019	2018	2017	2016	2015
Net income - GAAP	\$ (4,512)	\$ 14,313	\$ 31,903	\$ 51,943	\$ 81,453	\$ 2,571
Add back:						
Interest expense (income), net	1,476	517	2,579	1,045	(76)	(14)
Income tax provision	7,693	7,685	2,135	21,002	(28,026)	3
Depreciation and amortization	3,542	3,492	3,670	3,746	1,589	112
Stock-based compensation	24,547	21,998	19,082	15,429	9,768	4,051
Change in fair value of contingent consideration	-	-	(763)	(7,378)	957	-
Debt issuance costs	88	88	-	286	-	-
Fair value adjustments on equity investment	4,200	-	-	-	-	-
Asset impairment charge	-	-	2,704	7,235	-	-
Gain on sale of asset	-	-	-	-	(1,750)	-
Expense of acquired in-process research & development	500	500	1,700	1,000	-	-
Expense related to collaboration with Tyme	2,500	-	-	-	-	-
Severance	700	455	466	268	-	-
Restructuring charge	-	-	7,911	-	-	-
Legal settlement	-	-	-	1,650	-	-
Adjusted Non-GAAP EBITDA	\$40,734	\$49,048	\$71,387	\$96,226	\$63,915	\$6,723